Basic-Translational-Clinical Roundtables integrate basic, translational, and clinical aspects of a disease or disorder with particular emphasis on new developments, controversies, or updates. These interactive panel discussions encourage debate and conversation from clinician-scientists at all levels. Basic-Translational-Clinical Roundtables taking place during Neuroscience 2019 are listed below.
Mechanisms of Drug Addiction: A Translational Perspective
Trevor W. Robbins, PhD
University of Cambridge
This roundtable will focus on translatability of basic research in animals to human research in addiction in order not only to understand neurobehavioral mechanisms of addiction, but also to define new strategies for discovery of clinical treatments, especially regarding the current opioid crisis. Topics to be discussed include the neural systems underlying addiction, neuronal adaptations occurring within those systems, how different drugs of abuse produce addiction, and the role of aberrant learning and vulnerabilities in the drive to addiction.
Exoskeletons and Robotics for Neurorehabilitation
Ann M. Spungen, EdD
Icahn School of Medicine at Mount Sinai
This session will include a state-of-the-art overview of the use of robotics and exoskeletons in populations with neurological impairments. Specific presentations will include upper body robotic interventions for functional and neurological gains, robotic interventions for children with neurological impairments, and lower extremity exoskeletons for over ground ambulation. The lower extremity exoskeletal-assisted walking data will be presented from a randomized, controlled clinical trial.
Gene Therapy in Neurological Diseases
Asa Abeliovich, MD, PhD
Gene therapy has advanced rapidly in the past five years, with technological advances and encouraging early clinical studies. This roundtable will focus on the opportunities and challenges as the field progresses, with a focus on the development of disease-modifying therapies that address urgent unmet needs of patients with neurological disorders. Discussion topics will include: technologies that are driving the field, with a focus on AAV platforms; leveraging advances in neurogenetics to identify validated therapeutic targets and patient subpopulations; rare monogenic disorders and clinical therapeutic strategies; the pursuit of gene therapy approaches for genetically complex disorders; and CNS region- and cell-selective approaches.